Cytarabine (
ara-C) is the key agent for treating
acute myeloid leukemia. After being transported into leukemic cells,
ara-C is phosphorylated, by several
enzymes including
deoxycytidine kinase (dCK), to
ara-C triphosphate (
ara-CTP), an active metabolite, and then incorporated into
DNA, thereby inhibiting
DNA synthesis. Therefore, the cytotoxicity of
ara-C depends on the production of
ara-CTP and the induction of apoptosis. Here, we established a new
ara-C-resistant
acute myeloid leukemia cell line (HL-60/ara-C60) with dual resistance characteristics of the anti-antimetabolic character of decreased
ara-CTP production and an increase in the antiapoptotic factors Bcl-2 and Bcl-XL. We further attempted to overcome resistance by augmenting
ara-CTP production and stimulating apoptosis. A relatively new
nucleoside analog, 9-β-d-arabinofuranosylguanine (
ara-G), and the small molecule Bcl-2 antagonist
YC137 were used for this purpose. HL-60/ara-C60 was 60-fold more
ara-C-resistant than the parental HL-60 cells. HL-60/ara-C60 cells exhibited low dCK
protein expression, which resulted in decreased
ara-CTP production. HL-60/ara-C60 cells were also refractory to
ara-C-induced apoptosis due to overexpression of Bcl-2 and Bcl-XL. Combination treatment of
ara-C with
ara-G augmented the dCK
protein level, thereby increasing
ara-CTP production and subsequent cytotoxicity. Moreover, the combination of
ara-C with
YC137 produced a greater amount of apoptosis than
ara-C alone. Importantly, the three-
drug combination of
ara-C,
ara-G and
YC137 provided greater cytotoxicity than ara-C+ara-G or ara-C+YC137. These findings suggest possible combination strategies for overcoming
ara-C resistance by augmenting
ara-CTP production and reversing refractoriness against the induction of apoptosis in
ara-C resistant leukemic cells.